Stifel analyst Annabel Samimy raised the firm’s price target on Supernus (SUPN) to $55 from $50 and keeps a Hold rating on the shares as part of a 2026 outlook note for the analyst’s Biopharma coverage.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SUPN:
- Supernus Pharmaceuticals: Strategic Growth, Clinical Advances, and Strong Financial Synergies Drive Buy Rating
- Supernus management to meet virtually with Cantor Fitzgerald
- Bank of America Highlights Five Stocks It Says Still Offer Clear Upside in 2025
- Supernus Pharmaceuticals’ Earnings Call: Growth Amid Challenges
- Supernus Pharmaceuticals Reports Strong Q3 2025 Growth